Protein-protein interactions (PPIs) play key roles in all cellular processes and hence are useful as potential targets for new drug development. To facilitate the screening of PPI inhibitors as anticancer drugs, the authors have developed a highthroughput screening (HTS) system using an in vitro protein fragment complementation assay (PCA) with monomeric Kusabira-Green fluorescent protein (mKG). The in vitro PCA system was established by the topological formation of a functional complex between 2 split inactive mKG fragments fused to target proteins, which fluoresces when 2 target proteins interact to allow complementation of the mKG fragments. Using this assay system, the authors screened inhibitors for TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer PPIs from 123,599 samples in their natural product library. Compound TB1 was identified as a specific inhibitor for PPI of PAC3 homodimer. TB1 strongly inhibited the PPI of PAC3 homodimer with an IC 50 value of 0.020 µM and did not inhibit PPI between TCF7/β-catenin and PAC1/PAC2 even at a concentration of 250 µM. The authors thus demonstrated that this in vitro PCA system applicable to HTS in a 1536-well format is capable of screening for PPI inhibitors from a huge natural product library. (Journal of Biomolecular Screening 2009:970-979) 
INTRODUCTION
P rotein-protein interactions (ppis) play key roles in all cellular processes and functions because proteins form specific noncovalent complexes with other proteins in cells. Recently, many PPIs have been validated as relevant pharmaceutical targets using modern proteome analyses. Thus, PPI regulator screening is a means to discover novel drugs. Representative PPI detection assays and systems include the 2-hybrid system for mammalian and yeast cells, co-immunoprecipitation, enzymelinked immunosorbent assay (ELISA), fluorescence resonance energy transfer (FRET), antibody or other protein microarrays or chips, and systems based on surface plasmon resonance (SPR) and mass spectrometry. 1, 2 However, these assays require special equipment and techniques or have limited throughput. Here, we have developed a novel in vitro protein fragment complementation assay (PCA) for easy and high-throughput screening (HTS) of PPIs by using monomeric Kusabira-Green protein (mKG) as a fluorescent reporter protein.
PCAs were first implemented in the split-ubiquitin technique, 3 wherein ubiquitin is first split into 2 inactive fragments, which are then fused to either of the 2 interacting target proteins, bait and prey. In this assay, complementation between ubiquitin fragments due to the interaction of 2 target proteins restores the function of ubiquitin, which leads to the consequent degradation of the ubiquitinated reporter protein by ubiquitin-dependent proteases in cells. Other enzymes such as adenylate cyclase 4 and anthranilate isomerase 5 have also been used for PPI screening based on similar split protein systems in several organisms. However, all these approaches generate indirect and time-shifted responses and tend to generate high numbers of false positives. To observe PPI directly in cells, the reporter protein itself is split into 2 inactive fragments that are fused to bait and prey. An interaction between the fused bait and prey restores the function of the fragmented reporter protein. The reporter protein used in such systems includes enzymes such as galactosidase, 6 dihydroforate reductase, 7 lactamase, 8 and luciferase [9] [10] [11] [12] [13] that convert chromogenic, fluorogenic, or luminescent substrates. On incubation with the substrate, these enzyme-based PCAs amplify the signal; however, the concentration and incubation time of the substrate, which depends on the target proteins, have not been optimized thus far. Recently, split fluorescent proteins, such as yellow fluorescent protein 14 and green fluorescent protein (GFP), 15 have been used in PCAs; this method has been termed bimolecular fluorescence complementation (BiFC). Although folding processes and chromophore formation of split autofluorescent proteins are slow, these proteins form tight complexes. They also do not need any substrate, which results in reduction of the fluorescence background. Therefore, split fluorescent proteins have been exploited in multiplexed protein interaction assays and have been used for the evaluation of drug targets at the cell level. [16] [17] [18] Furthermore, in vitro PCAs with split GFP have also been reported; however, these assays can be cumbersome because they require the purification, denaturing, and refolding of split GFP-fused proteins expressed in Escherichia coli. 14, 19, 20 In the present study, we developed an in vitro PCA using mKG that is applicable to HTS; the system is advantageous in that it is very easy and simple to handle and does not require protein purification and refolding ( Fig. 1) .
A monomeric fluorescent reporter protein (218 amino acids) derived from corals, mKG exhibits maximum excitation at 494 nm and maximum emission at 506 nm. 21, 22 We have previously reported that in mammalian cells, when mKG splits into 2 inactive fragments fused to bait and prey proteins, it fluoresces due to the interaction between the target proteins. 21 In our previous system, N-and C-terminal fragments of mKG cannot approach each other if the expressed target proteins do not interact, and thus the protein does not emit fluorescence. However, when the bait and prey interact, the split mKG fragments spatially approach each other, and the effective local concentration of mKG fragments increases. As a result, mKG fragments form a structure that is sterically capable of fluorescing before separating and the chromophore emits fluorescence. Hence, a fluorescent signal can be detected, depending on the fused target protein-protein interaction (PPI). In this study, we improved this in vivo system to an in vitro system. The 2 split fragmentfused proteins, which are independently prepared using a wheat germ cell-free protein synthesis system, are simply mixed, and the fluorescence emitted due to mKG complementation by target protein interaction is measured.
On the basis of this system, we have constructed PCAs for 3 PPIs-T cell factor 7 (TCF7) with β-catenin, 23 proteasome assembling chaperone (PAC)1 with PAC2, 24 and the self-association of PAC3 homodimer, 25 with each playing important roles in cancer cells-and investigated the assay conditions in detail using TCF7/β-catenin. β-catenin is a multifunctional protein that binds to TCF and activates the transcription of cell cycle regulatory proteins. In colorectal cancers, stabilization of β-catenin and the resulting stimulation of TCF-mediated transcription promote cellular proliferation. 23 Therefore, inhibition of the PPI of TCF7/ β-catenin is expected to suppress cancer cell proliferation. PAC1, PAC2, and PAC3 are assembly factors of the 20S proteasome and are essential for proteasome activity. 24, 25 The proteasome regulates protein expression and function by ubiquitinated protein degradation and also contributes to the clearance of abnormal and misfolded proteins in cells. Cancer cells require higher proteasome activity than do normal cells to proliferate continuously. Proteasome inhibition may prevent degradation of proapoptotic factors, permitting activation of programmed cell death in neoplastic cells possessing antiapoptotic pathways. Therefore, we screened inhibitors of these PPIs as potential anticancer drugs from a natural product library that includes microbial metabolites, plant extracts, and marine natural products.
MATERIALS AND METHODS

Reagents and devices
All reagents were of analytical grade or comparable. Black 384-well and 1536-well screening plates were purchased from Greiner Bio-One (Monroe, NC; cat. no. 784900) and Corning 
Preparation of proteins
Our new technology was used to prepare proteins in vitro. 26 The binding domains of TCF7L2 (amino acids 1-67) and β-catenin (CTNNB, amino acids 137-665) and full-length PAC1, PAC2, and PAC3 genes were used as targets for PPI and were cloned into a Gateway entry plasmid (Invitrogen, Carlsbad, CA). To construct template plasmids, the 5-µL LR reaction mixture (Invitrogen) was incubated at 25 °C for 17 h with 2 ng each of Gateway entry clone, 10 ng of linearized Gateway destination vector, 1 µL of LR Clonase enzyme mix (Invitrogen), and LR reaction buffer (Invitrogen).
Next, PCR was carried out to prepare templates for transcription. The PCR reaction mixture (50 µL) contained 0.2 µM primers, 0.2 mM dNTPs, 2 µL LR reaction mixture for supplying the template DNA, 0.63 units of KOD Dash polymerase (Toyobo, Osaka, Japan), and 10% (v/v) DMSO. The PCR parameters were as follows: 1 min at 95 °C for primary denaturation and 30 cycles consisting of 20 s at 94 °C for denaturation, 5 s at 55 °C for annealing, and 4 min at 74 °C for extension. The PCR primers were designed to amplify the region from upstream of the SP6 promoter to 17 kb downstream of the attR2 site. The PCR products (50 µL) were transcribed in vitro at 37 °C for 17 h in 80 mM HEPES/KOH (pH 7.8), 16 mM magnesium acetate, 2 mM spermidine, 10 mM dithiothreitol (DTT), 2.5 mM of each nucleotide triphosphate (ATP, UTP, GTP, CTP), 40 units of ribonuclease inhibitor (Toyobo, Japan), and 150 U of SP6 RNA polymerase (Takara, Shiga, Japan). The mRNA fractions were used for translation without purification.
Protein synthesis was conducted by the bilayer method. 27 Wheat germ extracts were purchased from Cell Free Sciences (WEPRO7240; Tokyo, Japan) and ZoeGene (HPOWG; Tokyo, Japan). Standard buffers included in these kits for translation were used as an upper layer. The lower layer (13.6 µL) contained 7.5 µL of mRNA from the in vitro transcription, 8.6 mg of creatine kinase, 26 units of ribonuclease inhibitor, and 5 µL of wheat germ extract, and the volume was adjusted for optimal yield of each target. The reaction mixture was incubated at 26 °C for 17 h.
Assay design
The protein solutions prepared by the in vitro translation system were diluted with phosphate-buffered saline (PBS), and 10 µL of each protein solution was dispensed into a 384-well black plate using a Multidrop Combi dispenser. After incubation at room temperature for 17 h, the fluorescence was measured using an EnVision reader (dichroic mirror: 485 nm, excitation filter: 460-480 nm, emission filter: 495-540 nm).
HTS
Aliquots of 3 µL of a protein solution were dispensed into a 1536-well plate using a Multidrop Combi dispenser, and 0.1 µL of samples for screening dissolved in DMSO was added using a Multi-dispenser ADS-348-8. After incubation at room temperature for 1 h, 3 µL of the other protein solution was dispensed. After incubation for 17 h, fluorescence was measured using an EnVision reader. Active samples in the screen were selected as those exhibiting ≥70% inhibition compared with controls treated with 100 µM oleic acid.
Statistical analysis
The Z′ factor was used to evaluate assay performance. The Z′ factor is a dimensionless parameter that ranges from 1 (infinite separation) to <0. It is defined as Z′ = 1 -(3σc+ + 3σc-)/|µc+ -µc-|, where σc+, σc-, µc+, and µcare the standard deviations (σ) and averages (µ) of the high (c+) and low (c-) controls. 28
Natural product library
Our in-house natural product library was used as a source of samples for screening by the in vitro PCA using mKG. The library contained 123,599 diverse samples of crude metabolites of actinomycetes (69,966 samples), bacteria (4160 samples) except for actinomycetes, fungi (40,640 samples), plant extracts (4160 samples), and compounds isolated from microorganism metabolites (4353 samples) and marine natural products (320 samples). All samples were dissolved in DMSO.
Screening data management
Screening data files from the EnVision reader were loaded into a custom-built suite of modules for compound registration, plating, and data management that is managed using ActivityBase 6.0 (ID Business Solutions, Guildford, UK). Data were analyzed for samples exhibiting ≥70% inhibition of the target PPI but ≤30% inhibition of nontarget PPIs based on SARview (ID Business Solutions).
Isolation of active compounds
The compounds producing microorganisms were cultured in fermentation media suitable for each strain. The mycelial extract or supernatant of the fermentation broth was extracted with ethyl acetate or n-butanol, and the organic layer was evaporated to dryness. The dried residue was separated using normal or reversed-phase medium-pressure liquid chromatography to yield the active fraction. The active fraction was further purified by preparative reversed-phase high-performance liquid chromatography (HPLC). The structures of active compounds were determined on the basis of liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) spectroscopic data.
RESULTS
In vitro preparation of proteins
We used a wheat germ cell-free protein synthesis system to prepare split mKG fragment proteins fused to target proteins. This system has excellent throughput, offers an easy process with high reproducibility, and the proteins synthesized by this system show good folding. mKG fragments fused to 3 sets of interacting target proteins-TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer-were synthesized by this system, and each yielded a soluble fraction. The yields of TCF7-and β-cateninfused proteins were approximately 15 µg/mL and 8 µg/mL, respectively. The yields of PAC1-and PAC2-fused proteins were both 33 µg/mL. The yields of mKG_N-PAC3 and mKG_C-PAC3 were 11 µg/mL and 16 µg/mL, respectively. Because this wheat germ extract emitted hardly any background fluorescence, these protein solutions were not further purified but were used directly for the following experiments.
Assay design
We selected the PPI of TCF7/β-catenin to evaluate the HTS system using an in vitro PCA with mKG and initially investigated the incubation time of the 2 split mKG-fused proteins. These proteins, individually prepared by the in vitro synthesis system, were simply mixed, incubated at room temperature, and the fluorescence sequentially measured by a microplate reader. The fluorescence was first detectable within 4 h and reached a maximum by 20 h ( Fig. 2A) . Thus, the following experiments were carried out at the incubation time of 17 h.
To determine the position at which the TCF7 or β-catenin interaction domains fuse with the split mKG fragments, we constructed 8 patterns of fragments as follows: N-and C-terminal mKG fragments (designated as mKG_N and mKG_C, respectively) were fused to the N-and C-termini of TCF7 (forming TCF7-mKG_N, mKG_N-TCF7, TCF7-mKG_C, and mKG_C-TCF7), and mKG_N and mKG_C were fused to the N-and C-termini of β-catenin (forming β-catenin-mKG_N, mKG_Nβ-catenin, β-catenin-mKG_C, and mKG_C-β-catenin). These 8 split mKG-fused proteins were mixed in 8 combinations without dilution. All combinations showed high fluorescent values compared with the negative control (wheat germ extract; Fig. 2B) . In particular, the TCF7-mKG_N/β-catenin-mKG_C and mKG_N-TCF7/β-catenin-mKG_C combinations exhibited higher values, with a signal-to-background (S/B) ratio of 70:1.
Next, we investigated the dilution ratio of protein solutions to screen PPI inhibitors. The S/B ratios of all combinations were reduced by the dilution of protein solution with PBS. However, the TCF7-mKG_N/β-catenin-mKG_C combination showed an S/B ratio of 6:1, even at a dilution ratio of 1:32 (Fig. 2B) . Hence, the TCF7-mKG_N/β-catenin-mKG_C combination was used for screening of PPI inhibitors from the natural product library. Likewise, the combinations and dilution ratios for the PAC1/PAC2 and PAC3 homodimer interactions were established to have an S/B ratio of around 5:1, as shown in Table 1 , and were used in this manner for the following experiments.
To evaluate whether competition by the corresponding FLAG-tagged target proteins (TCF7-FLAG, PAC2-FLAG, and PAC3-FLAG) inhibits PPI of TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer, we carried out competition experiments. TCF7-FLAG, PAC2-FLAG, and PAC3-FLAG were added into these assay systems as competitors to the mKGtagged target at a ratio of 1 to 14:1, and the fluorescence was measured. In all PPIs, FLAG-tagged competitor inhibition was confirmed ( Fig. 2C) , implying that the fluorescence emitted in this system is caused by interaction between the bait and prey. However, the inhibitory activity of FLAG-tagged PAC3 was insufficient to eliminate the target PPI because FLAG-tagged PAC3 is capable of self-assembly into a homodimer. In addition, the inhibitory activities differed among the target PPIs. These differences may depend on the stability and intensity of each PPI.
For HTS in a 1536-well format, we miniaturized this PCA system from the 384-well format to the desired 1536-well format. We were able to perform the PCA in a 1536-well plate with 70% less material than the 384-well format. As a result, the S/B ratio in the 1536-well format assay was identical to that in the 384-well format. As a next step, we evaluated the assay performance for HTS by measuring the coefficients of variation (CVs) and the Z′ factor. The Z′ factor has been widely accepted by the HTS community for the evaluation of assay quality and performance. The control data points in 384-and 1536-well plates for each target showed very little variability, with CVs in the 3.3% to 7.6% range and calculated Z′ values of 0.71 to 0.88 (Fig. 3) . These results imply that this assay has an excellent assay performance for HTS. Consequently, we used this in vitro PCA system with a 1536-well plate to screen PPI inhibitors as potential anticancer drugs.
Screening of PPI inhibitors from a natural product library
We selected 3 PPI targets-TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer-to screen for anticancer drugs. These PPIs have been shown to play important roles in the growth of cancer cells ( Table 1) . For library screening, a total of 123,599 samples were screened per 1536-well plate, and 20 plates target PPIs-TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer-yielded 311 (0.25% of total samples), 399 (0.32%), and 1503 (1.21%) hit samples, respectively ( Table 2) . Moreover, the selectivity of hits for each target was assessed by criteria defined as target PPI inhibition ≥70% and other PPI targets ≤30%. Thus, 18 (0.01% of total samples), 40 (0.03%), and 257 (0.21%) hits were obtained by selection for TCF7/βcatenin, PAC1/PAC2, and PAC3 homodimer, respectively ( Table 2) . Next, we evaluated the reproducibility and dose dependency of target-selective hit samples. In consequence, no hits for TCF7/β-catenin, 2 hits for PAC1/PAC2, and 9 hits for PAC3 homodimer were selected. The 2 samples identified as hits for PAC1/PAC2 originated from actinomycete metabolites, and the 9 for the PAC3 homodimer were obtained from actinomycete (3 samples), fungal (3 samples), and plant (3 samples) metabolites. The microorganisms producing these samples were cultured in fermentation media, but inhibitory activity against target PPIs could not be confirmed for the culture broth of 2 strains. Accordingly, we isolated active compounds from 1 actinomycete sample for the PAC1/PAC2 and from 2 actinomycete, 3 fungal, and 3 plant samples for the PAC3 homodimer interaction.
Identification of active compounds
To determine the structure of these inhibitors of the PAC1/ PAC2 and PAC3 homodimer PPIs, we carried out activityguided separation from the culture broth of producing strains and plant extracts. The active compounds were determined by LC/MS and NMR spectroscopic data except for 3 unknown compounds (TB1, JBIR-22, and TN01).
The compound TAN 1323D, isolated from an actinomycete metabolite, was an inhibitor of PAC1/PAC2 (Fig. 4) . TAN 1323D inhibited the interaction between PAC1 and PAC2 with an IC 50 of 19 µM and showed inhibitory activity for PAC3 homodimerization and the TCF7/β-catenin interaction with IC 50 values of 32 and 40 µM, respectively (Table 3, Fig. 5) .
Several inhibitors of PAC3 homodimerization were obtained from metabolites of actinomycetes, fungi, and plants ( Table 3 , Fig. 5 ). TB1, JBIR-22, TN-01, and linoleic acid were isolated from fungal metabolites; leucanicidin from an actinomycetal metabolite; and saponin analogs, including soyasaponins, from plants (Fig. 4) . The structures of TB1, JBIR-22, and TN-01 are still not clear, and thus structural elucidation of these compounds is now under way. Among these inhibitors, TB1 exhibited potent inhibitory activity and selectivity ( Table 3) . The IC 50 values of TB1 were 0.020 µM for the PPI of PAC3 homodimer, whereas TB1 did not show inhibitory activities against TCF7/β-catenin or PAC1/PAC2 interactions (IC 50 >250 µM). Therefore, we have obtained a superior PPI inhibitor with the potential of being a proteasome inhibitor.
DISCUSSION
In this report, we engineered a novel HTS system using an in vitro PCA with mKG to screen PPI inhibitors from a natural product library. This PCA assay system, which is simply performed by mixing 2 protein solutions without the need for a complicated process (solid-phase protein, washing and addition of substrate, etc.) or expensive instruments, is very easy and low cost. Furthermore, we easily performed plasmid construction, protein preparation, and plate screening. We constructed plasmids containing 8 fusion combinations between target genes and split mKG fragments in a short procedure using the Gateway system and prepared proteins without the need for purification by using our in vitro protein preparation system. In fact, when we evaluated the difference in assay data between crude and purified protein solutions using TCF7/β-catenin and PAC3 homodimer, the fluorescence of mKG with the crude proteins was the same as that of the purified proteins (data not shown). Furthermore, TB1 showed the same IC 50 values for purified PAC3 homodimer (0.02 µM) and TCF7/β-catenin (>250 µM) compared with crude proteins (Fig. 5) . These results imply that purification steps are not necessary for protein preparation for this assay. In addition, this PCA system could be easily miniaturized to a 1536-well format. The CV and the Z′ factor values of this PCA in both 384-and 1536-well formats were excellent. A report has already been published on a PCA using luciferase and a rapid cell-free approach to detect protein-protein, protein-DNA, and protein-RNA interactions. 29 However, Porter et al. 29 did not use a split-Venus (green fluorescent protein variant) in the PCA. In contrast to the difficulty in applying the bright fluorescent protein Venus, we succeeded in constructing a split-fluorescent protein (mKG), which also fluoresces more brightly than conventional GFP. We have already investigated the optimal positions of the split in mKG, the flexible linker, and the fusion between target protein and split mKG fragment for adaptation of this PCA system to mammalian cells. 19 Hence, an in vitro PCA system with mKG could presumably be easily constructed based on these data. Furthermore, we were able to use crude samples of microbial metabolites and plant extracts for screening; these are typically considered unsuitable for HTS because of fluorescent assay interference by their intrinsic fluorescence. However, we screened PPI inhibitors from our natural product library with this PCA system, which was applicable to HTS in a 1536-well format, and obtained target-specific inhibitors. Accordingly, these results indicated that this PCA system could readily accommodate various PPI targets and samples. The first screening of inhibitors for 3 targets-TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer PPIs-showed high hit ratios of 0.25%, 0.32%, and 1.21%, but selective hits for these targets were 0.01%, 0.03%, and 0.21%, respectively. These results imply that many samples nonspecifically bind these proteins and inhibit PPI. Moreover, linoleic acid, a fungal metabolite, was isolated as an inhibitor of PAC3 homodimerization. Other fatty acids, such as oleic acid and linolenic acid, also inhibited all 3 targets ( Table 3) . Because crude assay samples of microbial origin frequently include abundant fatty acids, it may be difficult to identify specific hits for a PPI target from the hits of first screening when using a natural product library. Thus, the ratio required to pick up selective hits may increase by delipidation of these samples of the natural product library. However, although this PCA system involves the abovementioned problems in HTS, we succeeded in isolating 8 PPI inhibitors with various chemical structures, such as macrolides, and saponins. These inhibitors do not have any essential common structural similarities. The molecular weights of these compounds ranged from 376 to 967, with an average of approximately 630, with the exception of the fatty acids. These results suggest that adequate molecular size is needed to inhibit the binding domains of PPI. Accordingly, a natural product library is thought to be the ideal sample source in the screening of PPI inhibitors because natural products have a variety of molecular sizes and structures compared with synthetic compounds.
We isolated TAN 1323D as an inhibitor of the PAC1-PAC2 interaction from an actinomycete metabolite. Derivatives of TAN 1323D, concanamycin, and bafilomycin are known V-ATPase inhibitors. 30 Because the mechanism of V-ATPase inhibition by concanamycin analogs is disruption of subunit interactions in the V-ATPase complex, 30 it is possible that concanamycin analogs could show inhibition of PPIs. Therefore, we tested the inhibitory activity of concanamycin A as a representative concanamycin analog on PAC1/PAC2 and PAC3 homodimer. Concanamycin A inhibited PPI of PAC1/PAC2 and PAC3 homodimer at higher IC 50 values (250 µM) than TAN 1323D (data not shown). Hence, TAN 1323D has a selective inhibitory effect of the PAC1/PAC2 PPI, an effect distinct from other concanamycin analogs.
We also demonstrated that TB1, the specific inhibitor of PAC3 homodimerization, was identified by this system from a fungal metabolite. PAC3 is the assembly factor of 20S proteasome and essential for proteasome activity. 25 The proteasome inhibitor bortezomib has been used as a clinical agent for relapsed multiple myeloma and mantle cell lymphoma. 31 TB1 may be a precious lead compound for developing anticancer drugs. Bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity and inhibits proteasome activity. In contrast, because the target site of TB1 is the PPI of PAC3 homodimer, a different mode of proteasome inhibitory activity is expected. Studies on detailed biological activities, including the inhibition of proteasome activity in cancer cells, are now under way.
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